Ariad Pharmaceuticals Inc fka ARIA

[Whosetosay]

There must be some, albeit relatively modest consideration of a few intagibles in the pps, i.e. the proprietary lab techniques/molecules in progress, and, irrespective of what some would deny, a buyout premium. I think the adjustments would be to mostly lower 113, shave pona a bit.

Most biotech buyouts have a mild, yet incremental positive impact on ARIA pps. '113 data will be provide whole dollar changes to mix, and redistribute/adjust the respective components in the price accordingly.